Is ProQR Therapeutics N.V. (PRQR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 9.2% / 30% | 79.7% / 30% | 1.1% / 30% | 17.2% / 5% | ✗ NOT HALAL |
| DJIM | 9.2% / 33% | 79.7% / 33% | 1.1% / 33% | 17.2% / 5% | ✗ NOT HALAL |
| MSCI | 10.3% / 33% | 89.0% / 33% | 1.2% / 33% | 17.2% / 5% | ✗ NOT HALAL |
| S&P | 9.2% / 33% | 79.7% / 33% | 1.1% / 33% | 17.2% / 5% | ✗ NOT HALAL |
| FTSE | 10.3% / 33% | 89.0% / 33% | 1.2% / 50% | 17.2% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -192.9% | |
| Net Margin | -258.1% | |
| Return on Equity (ROE) | -61.2% | |
| Return on Assets (ROA) | -19.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$53M |
| Free Cash Flow | -$54M |
| Total Debt | $16M |
| Debt-to-Equity | 32.3 |
| Current Ratio | 3.1 |
| Total Assets | $113M |
Price & Trading
| Last Close | $1.50 |
| 50-Day MA | $1.60 |
| 200-Day MA | $2.06 |
| Avg Volume | 410K |
| Beta | 0.1 |
|
52-Week Range
$1.07
| |
About ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ProQR Therapeutics N.V. (PRQR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ProQR Therapeutics N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ProQR Therapeutics N.V.'s debt ratio?
ProQR Therapeutics N.V.'s debt ratio is 9.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.3%.
What are ProQR Therapeutics N.V.'s key financial metrics?
ProQR Therapeutics N.V. has a market capitalization of $144M, and revenue of $16M. The company maintains a gross margin of 100.0% and a net margin of -258.1%. Return on equity stands at -61.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.